Kashiv BioSciences has signed an exclusive licensing agreement with Amneal Pharmaceuticals for the commercialization of ADL018, a biosimilar version of Xolair (omalizumab), across the US. ADL018 is being investigated under the P-III clinical trial initiated during Q3’23
ADL018 is intended for the treatment of all the indications of omalizumab incl. severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), food allergies, & chronic spontaneous urticaria
Furthermore, the financial terms of the agreement are undisclosed with any incremental expenses linked to these products considered within Amneal’s guidance
Ref: Businesswire | Image: Kashiv
Related Post:- Kashiv BioSciences Reports the First Patient Enrolment of ADL018 (biosimilar, omalizumab) in the P-III Clinical Study for Chronic Spontaneous Urticaria
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
